Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Epizyme Inc (NQ: EPZM ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Epizyme Inc < Previous 1 2 Next > Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update August 09, 2022 From Epizyme, Inc. Via Business Wire EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM July 12, 2022 From Kahn Swick & Foti, LLC Via Business Wire EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM June 27, 2022 From Kahn Swick & Foti, LLC Via Business Wire Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027 June 28, 2022 Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... Via FinancialNewsMedia EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders June 27, 2022 From Halper Sadeh LLP Via Business Wire Ipsen to acquire Epizyme, expanding its portfolio in oncology June 27, 2022 From Epizyme, Inc. Via Business Wire Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting June 02, 2022 From Epizyme, Inc. Via Business Wire Epizyme To Participate in H.C. Wainwright Global Investment Conference May 17, 2022 From Epizyme, Inc. Via Business Wire Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update May 10, 2022 From Epizyme, Inc. Via Business Wire Epizyme Announces Date of First Quarter 2022 Financial Results May 03, 2022 From Epizyme, Inc. Via Business Wire Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 06, 2022 From Epizyme, Inc. Via Business Wire Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update March 15, 2022 From Epizyme, Inc. Via Business Wire Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results February 22, 2022 From Epizyme, Inc. Via Business Wire Epizyme Announces Pricing of Public Offering of Common Stock January 27, 2022 From Epizyme, Inc. Via Business Wire Epizyme Announces Proposed Public Offering of Common Stock January 26, 2022 From Epizyme, Inc. Via Business Wire Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates January 10, 2022 From Epizyme, Inc. Via Business Wire Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting December 12, 2021 From Epizyme, Inc. Via Business Wire Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting December 11, 2021 From Epizyme, Inc. Via Business Wire Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting December 02, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces Updates to Its Board of Directors November 18, 2021 From Epizyme, Inc. Via Business Wire Epizyme to Participate in Jefferies London Healthcare Conference November 12, 2021 From Epizyme, Inc. Via Business Wire Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update November 09, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 05, 2021 From Epizyme, Inc. Via Business Wire Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414 November 04, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces Date of Third Quarter 2021 Financial Results November 02, 2021 From Epizyme, Inc. Via Business Wire Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making November 01, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 07, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress September 14, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 20, 2021 From Epizyme, Inc. Via Business Wire Epizyme Announces CEO Succession August 09, 2021 From Epizyme, Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.